Chin Filler: Cost, Results and Who It Suits

Chin filler is a gel implant injected into the chin region to add volume.

All three chin fillers hold FDA approvals for chin augmentation in patients over 21; the Restylane Defyne and Restylane Lyft approvals describe it as augmentation of the chin region to improve the chin profile in mild to moderate chin retrusion, covered in the next section.

All three are hyaluronic acid gels with lidocaine: Juvéderm Voluma XC is Allergan's Juvéderm-family product, and Restylane Defyne and Restylane Lyft are Galderma's Restylane gels.

The Defyne and Lyft chin approvals describe placement under the skin and/or on top of the chin bone — "subcutaneous and/or supraperiosteal" injection, in the regulatory language.

Chin filler is one use of the dermal fillers used across the face in areas such as the lips, cheeks and smile lines.

Filler approvals are granted product by product and area by area, so a chin indication is its own regulatory event, not something a filler carries everywhere.

Amount is measured in milliliters, and the labels set per-treatment ceilings for the chin.

The Restylane Lyft label caps the chin at 4 mL per treatment including touch-up, with no more than 2 mL at any single injection site, and the Restylane Defyne label sets the same 4 mL maximum per patient per treatment, split between the chin and the area below the lower lip toward the pre-jowl sulcus.

These are safety ceilings, not recommended or typical amounts; how much filler any chin needs is an individual assessment made in person.

"Recessed chin" is the everyday term; the approval wording calls it chin retrusion — a chin that sits back from the surrounding profile.

Two of the three chin-approved fillers, Restylane Defyne and Restylane Lyft, are approved specifically for chin augmentation in mild to moderate chin retrusion, in patients over 21. Juvéderm Voluma XC is approved for chin augmentation too; the FDA approval records in our research name that use but do not quote Voluma XC's full chin indication, so we cannot say whether it names a severity range.

The words "mild to moderate" carry real weight: they are the severity range the Defyne and Lyft approvals name.

Severe retrusion sits outside what those approvals describe, and judging where a chin falls on that scale is part of a licensed provider's in-person assessment.

The labels also record who was not studied.

Allergan's ISI states that Voluma XC safety was not studied in patients under 22 or over 80 for chin augmentation, and that Voluma XC was not studied in people with significant loose skin of the chin, neck or jaw. "Not studied" means safety is unknown in those groups, not proven unsafe — the label simply gives no safety data there.

A chin that lacks projection and fullness under the chin are different problems with different treatments.

Kybella, a prescription drug, is FDA-approved only for moderate to severe fullness from submental (under-chin) fat in adults, and its label says it is not approved for fat outside that region.

Filler adds volume in the chin itself; Kybella reduces fullness beneath it.

Which — if either — fits a given chin is something a consultation can sort out.

Chin filler is the non-surgical route to chin projection: the volume comes from an injection, not an operation.

There is also surgery — chin augmentation (mentoplasty).

ASPS's cost pages give an average surgeon's fee of $3,641 for chin augmentation, a figure that excludes anesthesia, operating-room facilities and other expenses.

It is a national average surgeon's fee from ASPS's statistics, not a quote — and comparing it with a filler price means comparing a surgeon's fee with a practice's treatment price, which are not like-for-like numbers.

The chin is one of several areas where these products hold approvals: Voluma XC is also approved for cheek augmentation (2013) and temple hollowing (2023).

Whether treating one area or several makes sense for a profile is a consultation question, not something a guide can answer.

Multi-area plans are covered in facial balancing, and filler along the jaw in jawline filler.

As of October 20, 2026, only three fillers sold in the US carry an FDA-approved chin indication: Juvéderm Voluma XC, Restylane Defyne and Restylane Lyft with Lidocaine.

Defyne and Lyft are approved for chin augmentation in mild to moderate chin retrusion; Voluma XC is approved for chin augmentation, and the FDA records in our research do not quote its full chin indication.

All three indications are for patients over 21.

Each product also holds approvals elsewhere.

Voluma XC is approved for cheek augmentation (2013) and temple hollowing (2023).

Defyne and its sister product Refyne are approved for moderate to severe facial wrinkles and folds such as nasolabial folds (2016) — Refyne has no chin indication.

Lyft is approved for facial folds such as nasolabial folds, for cheek augmentation and age-related midface contour deficiencies (2015), and for volume deficit in the backs of the hands (2018).

Everything else that gets injected into chins — Restylane Refyne, the RHA collection, Radiesse, Sculptra, Juvéderm Volux — holds no chin indication, so chin injections with those products are off-label: the use appears on no current US label for those products.

Ask any provider which filler they plan to use in your chin, and why they expect it to perform well there.

Our research found no national list price for chin filler.

Filler is priced per treatment, and the maker names the variables: Allergan, which makes Voluma XC, does not publish a price — it says pricing varies by the Juvéderm product used, the amount of product used and the provider.

For a fuller breakdown, see how much chin filler costs.

We could not find a published per-syringe price for Voluma XC, Restylane Lyft or the other fillers covered in our research — none of the manufacturer or ASPS pages read on October 20, 2026 lists one.

A single "chin filler cost" figure with no source and date behind it cannot be checked.

Ask each practice for its per-syringe price on the specific product it uses, and what a touch-up would cost.

The closest national anchor is ASPS's average cost of $715 for hyaluronic acid fillers, from its latest statistics.

That is an average physician fee across filler procedures — not a med spa price, not a chin-specific price, and not what one practice will charge you.

• The product. Allergan names the product itself as the first pricing variable.
• The amount used. The labels' chin ceilings sit at 4 mL per treatment — Lyft's including touch-up; a treatment using a fraction of that does not price the same.
• The provider. Allergan names the provider as the third variable, and prices differ practice to practice.

Both manufacturers behind the chin-approved fillers run rewards programs.

Allergan's Allē earns points on qualifying treatments including Juvéderm fillers, at a stated 100 points = $10, and Galderma's ASPIRE earns points on qualifying Galderma treatments, including Restylane.

Each program's terms come from its maker and are worth reading before you count on the value.

The clearest duration statement for the chin belongs to Allergan, and it is an upper bound: the company's stated duration for Voluma XC in the chin is "up to 1 year with optimal treatment." "Up to" marks the best case under the maker's own protocol — Allergan's wording, not a typical result and not a promise.

The Restylane labels publish trial responder rates rather than a duration for the chin.

In the Restylane Lyft chin trial, the blinded-evaluator responder rate — at least a 1-grade chin improvement — was 83.6% at month 3, 75.5% at month 6, 69.1% at month 9 and 69.7% at month 12.

In the Defyne chin trial, 86.1% of treated subjects had at least a 1-point improvement in chin profile at week 12, versus 6.5% of untreated controls, and the difference over no treatment stayed statistically significant through week 48.

A responder rate is not a timer.

It counts how many trial subjects still showed a measurable improvement at a study visit; it does not say how long any one person's result lasted, and a Lyft figure never transfers to Defyne or Voluma.

We could not find a label or trial that states a typical duration for Defyne or Lyft in the chin — the responder curves are the closest published figures.

For what results can look like, see chin filler before and after.

Common side effects come from the manufacturers' safety sheets.

The Juvéderm ISI — the sheet covering the family Voluma XC belongs to — lists redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration and itching as the most common side effects, and says most resolve within 30 days.

Ask for the patient information sheet for whichever product your provider plans to use, since each label stands on its own studies.

FDA's serious warning covers every filler, wherever it is placed: the agency calls unintentional injection into a blood vessel the most concerning dermal filler risk.

The chance is low, but a blocked vessel can cause tissue death (necrosis), vision abnormalities including blindness, or stroke.

Restylane's labels add site context: rare ischemic events affecting the eye (vision loss) and the brain (stroke) have been reported after facial filler treatments, and many of the events requiring medical intervention involved the glabella, the nose and the periorbital area (around the eyes) — sites the labels note sit outside those devices' indications.

Who may inject — and under whose supervision — is set by state law, not by one national rule.

AmSpa, a med spa trade association, takes the position that injecting botulinum toxin — a prescription (legend) drug — is the practice of medicine, to be done by a physician, an independent-practice nurse practitioner or another licensed professional working within their state-regulated scope.

AmSpa also describes a delegation model it says is common: nurses and other licensed professionals injecting after documented training, a patient exam and a treatment order from a physician (or a delegated PA/NP), with the physician on site or promptly reachable.

AmSpa frames all of this as operating under rules that vary by state, so who holds the syringe at a given practice depends on where you live.

Searching "chin filler near me" is the easy part; the checks below are what sort the results.

For the staffing rules in depth, our injector credentials guide explains the letters (RN, NP, PA, MD), the med spa laws by state guide covers supervision, and the how to choose a med spa checklist walks a visit end to end.